Hind͏ustan Laboratories IPO

Hindustan Laboratories Limited, incorporated in 2017, is a pharmaceutical company specializing in the manufacturing and supply of generic medicines. The company’s core business operates under a business-to-government (B2G) framework, where it primarily supplies its products to government institutions across India.

Business Model and Operations

• Core Focus: The company’s operations are centered on winning procurement contracts through a rigorous tendering process with central and state government agencies.
• Customer Base: Hindustan Laboratories serves a wide network, supplying products to 27 states and Union Territories. It served 343 customers in the six months ended September 30, 2025.
• Product Portfolio: The company’s product range includes 948 products across 15 therapeutic segments, such as anti-infectives, cardiac, and respiratory therapies. It has formulation capabilities across various dosage forms like tablets, capsules, and creams.

Manufacturing Facilities

• Unit 1: The company’s primary manufacturing facility is located in Palghar, Maharashtra. It is certified with WHO-GMP, GLP, and ISO 9001:2015, ensuring high-quality manufacturing standards.
• Unit 2: An additional manufacturing unit at the same Palghar facility is currently under commissioning. This unit is intended to support the company’s capacity expansion and will also be used to manufacture skincare cosmetic products.

Corporate Structure

The company is led by its promoters, Rajesh Vasantray Doshi, Kunjal C Dedhia, and Krishiv Rajesh Doshi. As of the filing date, the promoters hold a 99.99% stake in the company. The senior management team, including the Chief Financial Officer and the Company Secretary, possesses extensive experience in their respective fields, contributing to the company’s robust operational and financial management.

Industry Outlook

Indian Generic Pharmaceutical Market: A Government-Driven Growth Story

India’s pharmaceutical market is poised for significant growth, driven by a steady increase in government healthcare spending. Overall expenditure has shown a CAGR of 8.6% over the past four years, reaching ₹89,974 crores in FY25. The consumables segment, which includes pharmaceuticals, has demonstrated a CAGR of 8.1% between FY20-FY25.

Government spending on pharmaceuticals through tender-based procurement is expected to rise sharply, supported by national healthcare priorities and increased public-sector funding. Key growth drivers include:

• Expanding Government Programs: Initiatives like Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) and the National Tuberculosis Elimination Programme (NTEP) are driving demand for affordable generic medicines.
• Regulatory Shifts: Revised Schedule M provisions and the requirement for WHO-GMP certification have elevated entry barriers, favouring well-capitalized and quality-focused firms.
• Focus on Generic Substitution: A nationwide push to reduce healthcare costs is accelerating the adoption of generic medicines.

Within this landscape, the Indian generics market is witnessing robust growth across various therapeutic areas. Segments such as vitamins, blood-related, and anti-infectives are expected to register steady to high growth over the next five years, driven by increasing health awareness, government healthcare programs, and changing lifestyles.

How Will Hindustan Laboratories Limited Benefit

• The company is uniquely positioned to benefit from the 8.6% CAGR in government healthcare spending, with its business model almost entirely focused on the B2G segment.
• With a proven win ratio of 78.57% in recent tenders, the company is well-equipped to capture a larger share of the rising volume of government procurement contracts.
• The company’s diversified portfolio across high-growth segments like vitamins and blood-related therapies aligns perfectly with the projected growth in government spending in these areas.
• As regulatory barriers like Schedule M compliance become more stringent, the company’s WHO-GMP certified facility will become a significant competitive advantage.
• The company plans to expand its participation in government procurement by targeting a wider set of agencies and states, directly capitalizing on the expanding tender-based market.
• The strategic move to enter the skincare cosmetic segment via government tenders opens a new revenue stream, tapping into the high-growth Indian skincare market projected to grow at a 10% CAGR.
• The plan to expand internationally into semi-regulated and unregulated markets offers a significant growth avenue, leveraging its expertise in the B2G model to address a global market projected to reach US$ 68.6 billion by 2028.

Peer Group Comparison

Key Strategies for Hindustan Laboratories Limited

Position as a Leading Partner in the Domestic Government Healthcare Market

Hindustan Laboratories Limited intends to solidify its position by maximizing participation in government tenders. The company will leverage its dedicated tender team to systematically monitor upcoming opportunities and align its product portfolio with market requirements. By strategically managing working capital for earnest money deposits, it aims to bid for a larger number of contracts across a wider set of agencies and therapeutic categories.

Expand Internationally through Government Channels in Semi-Regulated and Unregulated Countries

The company plans to leverage its expertise in the B2G model to expand into international markets. The strategy involves participating in government tenders in semi-regulated and unregulated countries, for which it will obtain the necessary product approvals and import licenses. To support this, it will expand its sales and marketing team to focus on international business, attending trade fairs and showcasing its manufacturing facilities.

Leverage Existing Product Licenses for Timely Introduction of New Formulations

Hindustan Laboratories plans to capitalize on its existing product licenses to introduce new formulations in a timely manner. By deepening its product portfolio, particularly in higher-value segments, the company aims to improve its margins and participate in a larger number of tender categories. Its dedicated in-house product development team will be central to this strategy, focusing on new technologies to reduce production costs.

Expand Reach via Government Tender-Based Distribution of Skincare Cosmetic Products

To capture a share of the high-growth Indian skincare market, Hindustan Laboratories plans to begin manufacturing and supplying cosmetic products. Having received the necessary license from the Food & Drugs Administration (Maharashtra State), the company will participate in procurement tenders for products like face wash, sunscreen lotion, and hand wash, leveraging its existing B2G channels to distribute these new offerings.